JO
NMRA icon

John Overdeck’s Neumora Therapeutics NMRA Stock Holding History

John Overdeck’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Buy
2,244,829
+208,137
+10% +$396K ﹤0.01% 2403
2026
Q1 		$3.97M Buy
2,036,692
+729,004
+56% +$1.89M ﹤0.01% 2177
2025
Q4 		$2.34M Buy
1,307,688
+1,007,874
+336% +$2.21M ﹤0.01% 2316
2025
Q3 		$546K Sell
299,814
-288,518
-49% -$466K ﹤0.01% 2942
2025
Q2 		$431K Buy
588,332
+314,018
+114% +$238K ﹤0.01% 2651
2025
Q1 		$274K Buy
274,314
+226,024
+468% +$387K ﹤0.01% 2748
2024
Q4 		$512K Buy
48,290
+686
+1% +$8.22K ﹤0.01% 2531
2024
Q3 		$629K Sell
47,604
-124,916
-72% -$1.46M ﹤0.01% 2354
2024
Q2 		$1.7M Buy
+172,520
New +$1.78M ﹤0.01% 1657
2023
Q4 		– Sell
-58,500
Closed -$825K – 3302
2023
Q3 		$825K Buy
+58,500
New +$731K ﹤0.01% 2041

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

John Overdeck's NMRA Position: Q2 2026 in Review

John Overdeck increased its Neumora Therapeutics (NMRA) stake by 10% in Q2 2026, buying an estimated $396K and bringing the position to 2,244,829 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

John Overdeck first reported a position in NMRA in Q3 2023 and has held it in 10 quarters since. The position peaked at $3.97M in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • John Overdeck held 2,244,829 shares of Neumora Therapeutics worth $3.82M as of Q2 2026.
  • John Overdeck bought 208,137 Neumora Therapeutics shares in Q2 2026, an estimated $396K.
  • Neumora Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2403 holding.
  • John Overdeck first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • John Overdeck's Neumora Therapeutics position peaked at $3.97M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.